Who are Escitalopram + Bupropion SR's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Paroxetine+Bupropion, fluoxetine + Amfebutamone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/escitalopram-bupropion-sr.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Escitalopram + Bupropion SR — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Escitalopram + Bupropion SR (Escitalopram + Bupropion SR) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SSRI + NDRI combination. Area: Psychiatry / Mental Health.

marketed SSRI + NDRI combination Serotonin transporter (SERT); Norepinephrine transporter (NET); Dopamine transporter (DAT) Psychiatry / Mental Health Small molecule Live · refreshed every 30 min

Target snapshot

Escitalopram + Bupropion SR (Escitalopram + Bupropion SR) — National Institute of Mental Health (NIMH). This combination increases serotonin and norepinephrine signaling in the brain through selective serotonin reuptake inhibition and dopamine/norepinephrine reuptake inhibition.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Escitalopram + Bupropion SR TARGET	Escitalopram + Bupropion SR	National Institute of Mental Health (NIMH)	marketed	SSRI + NDRI combination	Serotonin transporter (SERT); Norepinephrine transporter (NET); Dopamine transporter (DAT)
Paroxetine+Bupropion	Paroxetine+Bupropion	Ministry of Health & Welfare, Korea	marketed	SSRI + NDRI combination antidepressant	Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT)
fluoxetine + Amfebutamone	fluoxetine + Amfebutamone	Shanghai Mental Health Center	marketed	SSRI + NDRI combination antidepressant	Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SSRI + NDRI combination class)

National Institute of Mental Health (NIMH) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Escitalopram + Bupropion SR — Competitive Intelligence Brief. https://druglandscape.com/ci/escitalopram-bupropion-sr. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab